Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Ordinary Shares, nominal value 0.05 GBP per share
-
Shares outstanding
-
84,213,667
-
Total 13F shares
-
80,348,842
-
Share change
-
+4,624,747
-
Total reported value
-
$8,573,414,626
-
Put/Call ratio
-
70%
-
Price per share
-
$106.71
-
Number of holders
-
242
-
Value change
-
+$831,687,917
-
Number of buys
-
139
-
Number of sells
-
214
Institutional Holders of Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share (VRNA) as of Q3 2025
As of 30 Sep 2025,
Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share (VRNA) was held by
242 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
80,348,842 shares.
The largest 10 holders included
Pentwater Capital Management LP, OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC), HBK INVESTMENTS L P, BlackRock, Inc., FIL Ltd, Frazier Life Sciences Management, L.P., Davidson Kempner Capital Management LP, GLAZER CAPITAL, LLC, NEA Management Company, LLC, and GOLDMAN SACHS GROUP INC.
This page lists
242
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.